TD Cowen raised the firm’s price target on Halozyme (HALO) to $90 from $79 and keeps a Buy rating on the shares. The firm adjusted price targets in the diagnostic tools group group as part of a Q4 preview. Investor sentiment continues to inflect upward with 2026 guidance updates “key for positioning within the sector recovery,” the analyst tells investors in a research note. TD is most positive on stocks “with clear multi-year frameworks and multiple avenues for upside to derisked growth assumptions.”
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HALO:
- Halozyme announces global collaboration, license agreement with Takeda
- Halozyme price target lowered to $75 from $79 at Morgan Stanley
- CoreWeave initiated, Shopify downgraded: Wall Street’s top analyst calls
- Skye Bioscience, Halozyme enter collaboration, license agreement
- Halozyme, Skye Bioscience announce global collaboration, license agreement